Biological evaluation of osteoporosis;Exploration biologique des ostéoporoses

Medecine Nucleaire

Volumn 28, Issue 2, 2004, Pages 77-84

  Souberbielle, Jean Claude ^a   Lawson Body, E ^a   Cormier, C ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Institut Cochin   (France)

Author keywords

Bone remodeling markers; Phosphocalcic metabolism; Primary osteoporosis; Secondary osteoporosis; Treatment follow up

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; OSTEOCALCIN; TELOPEPTIDE;

AGE; AGING; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; CALCIUM METABOLISM; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHOSPHATE METABOLISM; POSTMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; PRIMARY OSTEOPOROSIS; PUBERTY; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SECONDARY OSTEOPOROSIS;

EID: 2442507752     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kleerekoper M. Evaluation of the patient with osteoporosis or at risk for osteoporosis. in Osteoporosis 2nd Edition. Marcus R, Feldman D, Kelsey J Eds 2001, Academic Press, San Diego, Ca.
2. R, Marcus R. Beyond bone mineral density-Navigating the laboratory assessment of patients with osteoporosis. J Clin endocrinol Metab 2002, 87: 4429-4430.
3. Bilezikian J, Potts JT, Fuleihan G, Kleerekopet M, Neer R, Peacock M, Rastad J, Silverberg S, Udelsman R, Wells S. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002, 87: 5353-5361.
4. Nutt R, Martini G, Valenti R, Giovani S, Salvadori S, Avanzadi A. Prevalence of undiagnosed coeliac syndrome in osteoporotic women. J Intern Med 2001, 250: 361-366.
5. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int (1997) 7: 439-443.
6. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001, 86: 3086-3090.
7. Malabanan A, Veronikis E, Holick M. Redefining vitamin D insufficiency. Lancet 1998, 351: 805-806.
8. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas P, Meunier PJ. Vitamin D and calcium to prevent hip fractures in the elderly. N Engl J Med 1992, 327: 1637-1642.
9. Dawson-Hughes B, Harris S, Krall E, Dallal G. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med (1997) 337: 670-676.
10. Trivedi D, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ (2003) 326: 469-475.
11. Lips P. Vitamin D deficiency and secondary hyperparathyroidtsm in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocrine Reviews 2001, 22: 477-501.
12. Holick M. Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes (2002) 9: 87-98.
13. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? British Journal of Nutrition (2003) 89: 552-572.
14. Bischoff H, Stähelin H, Dick W, Akos R, Knecht M, Salis C, Nebiker M, Theiler R, Pfeifer M, begerow B, Lew R, Conzelmann M. Effetcs of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res (2003) 18: 343-351.
15. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr 1999, 69: 842-856.
16. Souberbielle JC, Lawson-Body E, Hammadi B, Sarfati E, Kahan A, Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 2003, 88: 3501-3504.
17. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinsky R, Meier D, Luckey M. 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87: 4431-4437.
18. Barzel U. Recommended testing in patients with low bone density. J Clin Endocrinol Metab [Letter] 2003 88: 1404-1405.
19. Kerstetter J, O'Brien K, Insogna K. Dietary protein, calcium metabolism, and skelettal homeostasis revisited. Am J Clin Nutr 2003, 78 (suppl): 584S-592S.
20. Garnero P, Bianchi F, Carlier MC, Genty V, Kamel S, Kindermans C, Plouvier E, Pressac M, Souberbielle JC (groupe de travail SFBC, marqueurs biochimiques du remodelage osseux). Les marqueurs biologiques du remodelage osseux: variations pré-analytiques et recommandations pour leur utilisation. Ann Biol Clin 2000, 58: 683-704.
21. Delmas P, Eastell R, Garnero P, Seibel M, Stepan J. The use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis Osteoporosis Int 2000, 11 Suppl 6: 2-17.
22. Miller P, Baran D, Bilezikian J, Greenspan S, Lindsay R, Riggs L, Watts N.. Practical applications of biochemical markers of bone turnover. Consensus of an expert panel. J Clin Densitometry 1999, 2: 323-342.
23. 11-Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2001, 19: 338-344.
24. Souberbielle JC, Carlier MC, Bianchi F, genty V, jacob N, jamel S, Kindermans C, Plouvier E, Pressac M, Garnero P. Enquête sur la prescription des marqueurs du remodelage osseux en milieu hospitalier. Ann Biol Clin 2002 60: 571-579.
25. Johnell O, Oden A, De laer C, Garnero P, Delmas P, Kanis J. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporosis Int 2002, 13: 523-526.
26. Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with Risedronate. J Bone Miner Res 2003 18: 1051-1056.
27. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas P, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporosis Int 2001, 12: 922-930.
28. Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas P. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 2003, 18: 1789-1794.